electroCore
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
200 Forge Way Ste 205, Rockaway, New Jer...Phone Number
(973) 290-0097Website
www.electrocore.comRevenue
$34.9 MillionStock Symbol
ECORIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About electroCore
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.Explore more
electroCore Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is electroCore your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when electroCore launches new products
Click to see if electroCore had a recent Job posting/layoffs
Check if electroCore has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once electroCore has new funding data
Check out if electroCore is spiking on competitors!
Earning: See what the market has to say on electroCore recently announced quarterly report
Website visits: Recent activity has been detected on your website
electroCore, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at electroCore
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to electroCore
Compare insights from companies similar to electroCore, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
electroCore is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
electroCore is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about electroCore.
electroCore financials insights
Gather financial insights about electroCore, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$50M
2016
Debt
$1.5M
2017
Series B
$70M
2018
Stock Offering
$78M
2020
Share Placement
$25M
Debt
$1M
2025
Stock/Share Issuance
$1.9M
electroCore Tech Stack
A closer look at the technologies used by electroCore
Most Recent Scoops
Person-Based
Earnings
electroCore has reported that its Quell product line generated in excess of $1 million in revenue for Q1 2026, up from approximately $400,000 in March 2026 and approximately $50,000 per month at the time of the NeuroMetrix acquisition in May 2025.
Earnings, Finance
Earnings
electroCore has reported Q1 2026 revenue growth of 43% year-over-year, driven primarily by new patient starts from prior periods and a recurring refill pipeline supported by the company's inside sales and customer experience organization.
Sales, Inside Sales, Customer Experience
Project
electroCore is pursuing a restructuring of its VA sales territories to increase presence at underperforming accounts and deepen penetration within its existing base of approximately 150 VA accounts, where approximately 80% of revenue is currently generated by approximately 20% of customers.
CRM, Sales, Account Management, Customer Retention & Development
Earnings
Earnings, Finance
electroCore News & Media
electroCore Announces Second Quarter 2026 Financial Results
Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, 2026.New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding electroCore
Sign Up For FreeTo access detailed company insights
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the... Read More
